{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:28:46Z","timestamp":1791340126400,"version":"4.3.1"},"reference-count":51,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,18]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>MPL is essential for the development of JAK2V617F-positive myeloproliferative neoplasms in vivo. Ablation or reduction of Mpl significantly reduces the pool of neoplastic hematopoietic stem cells.<\/jats:p>","DOI":"10.1182\/blood-2014-07-587238","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T21:29:19Z","timestamp":1414013359000},"page":"3956-3963","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":90,"title":["The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm"],"prefix":"10.1182","volume":"124","author":[{"given":"Veena","family":"Sangkhae","sequence":"first","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, NY;"},{"name":"Centre for Immunology and Infection, Department Biology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Leah","family":"Etheridge","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, NY;"},{"name":"Department of Biology, University of York, Heslington Campus, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kaushansky","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian S.","family":"Hitchcock","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University, Stony Brook, NY;"},{"name":"Centre for Immunology and Infection, Department Biology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111817520914100_B1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1359-6101(01)00030-2","article-title":"Thrombopoietin: a pan-hematopoietic cytokine.","volume":"13","author":"Geddis","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"issue":"8","key":"2019111817520914100_B2","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1182\/blood-2007-11-124859","article-title":"Incomplete restoration of Mpl expression in the mpl-\/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis.","volume":"113","author":"Lannutti","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111817520914100_B3","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2008-03-146084","article-title":"Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes.","volume":"113","author":"Tiedt","year":"2009","journal-title":"Blood"},{"key":"2019111817520914100_B4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1196\/annals.1349.018","article-title":"Thrombopoietin and the hematopoietic stem cell.","volume":"1044","author":"Kaushansky","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"2019111817520914100_B5","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1073\/pnas.96.6.3132","article-title":"Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia.","volume":"96","author":"Ihara","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111817520914100_B6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood.V97.1.139","article-title":"c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia.","volume":"97","author":"Ballmaier","year":"2001","journal-title":"Blood"},{"issue":"7","key":"2019111817520914100_B7","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"10","key":"2019111817520914100_B8","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2019111817520914100_B9","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2009.005918","article-title":"Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia.","volume":"94","author":"Liu","year":"2009","journal-title":"Haematologica"},{"issue":"6","key":"2019111817520914100_B10","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/jcb.23089","article-title":"The thrombopoietin\/MPL pathway in hematopoiesis and leukemogenesis.","volume":"112","author":"Chou","year":"2011","journal-title":"J Cell Biochem"},{"issue":"17","key":"2019111817520914100_B11","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"9464","key":"2019111817520914100_B12","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"2019111817520914100_B13","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"4","key":"2019111817520914100_B14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"52","key":"2019111817520914100_B15","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.","volume":"102","author":"Lu","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2019111817520914100_B16","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2007-07-102186","article-title":"The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.","volume":"111","author":"Wernig","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111817520914100_B17","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2012-12-473777","article-title":"A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis.","volume":"123","author":"Etheridge","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111817520914100_B18","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms.","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2019111817520914100_B19","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms.","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111817520914100_B20","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111817520914100_B21","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111817520914100_B22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"12","key":"2019111817520914100_B23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111817520914100_B24","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMc1109555","article-title":"Long-term outcome of treatment with ruxolitinib in myelofibrosis.","volume":"365","author":"Tefferi","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111817520914100_B25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1046\/j.1365-2141.1996.00297.x","article-title":"Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders.","volume":"92","author":"Li","year":"1996","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111817520914100_B26","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood.V88.5.1656.1656","article-title":"Ectopic expression of murine TPO receptor (c-mpl) in mice is pathogenic and induces erythroblastic proliferation.","volume":"88","author":"Cocault","year":"1996","journal-title":"Blood"},{"issue":"9","key":"2019111817520914100_B27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1056\/NEJM199802263380903","article-title":"Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.","volume":"338","author":"Moliterno","year":"1998","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111817520914100_B28","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1073\/pnas.1312148111","article-title":"JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.","volume":"111","author":"Etheridge","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111817520914100_B29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/gene.1030","article-title":"Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line.","volume":"30","author":"Constien","year":"2001","journal-title":"Genesis"},{"issue":"6","key":"2019111817520914100_B30","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood.V87.6.2162.bloodjournal8762162","article-title":"Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl.","volume":"87","author":"Alexander","year":"1996","journal-title":"Blood"},{"issue":"Suppl 1","key":"2019111817520914100_B31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/stem.5530140715","article-title":"Dissection of c-Mpl and thrombopoietin function: studies of knockout mice and receptor signal transduction.","volume":"14","author":"Gurney","year":"1996","journal-title":"Stem Cells"},{"issue":"9","key":"2019111817520914100_B32","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1182\/blood.V93.9.2859.409k23_2859_2866","article-title":"High-level expression of Mpl in platelets and megakaryocytes is independent of thrombopoietin.","volume":"93","author":"Cohen-Solal","year":"1999","journal-title":"Blood"},{"issue":"16","key":"2019111817520914100_B33","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1242\/dev.001818","article-title":"Dual role of Mpl receptor during the establishment of definitive hematopoiesis.","volume":"134","author":"Petit-Cocault","year":"2007","journal-title":"Development"},{"issue":"1","key":"2019111817520914100_B34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood.V92.1.4.413k38_4_10","article-title":"Role of c-mpl in early hematopoiesis.","volume":"92","author":"Solar","year":"1998","journal-title":"Blood"},{"issue":"25","key":"2019111817520914100_B35","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/blood-2008-12-192054","article-title":"Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential.","volume":"113","author":"Kent","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111817520914100_B36","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1182\/blood.V87.11.4544.bloodjournal87114544","article-title":"Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice.","volume":"87","author":"Ku","year":"1996","journal-title":"Blood"},{"issue":"12","key":"2019111817520914100_B37","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1182\/blood.V87.12.4998.bloodjournal87124998","article-title":"The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells.","volume":"87","author":"Sitnicka","year":"1996","journal-title":"Blood"},{"issue":"3","key":"2019111817520914100_B38","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1172\/JCI0215430","article-title":"Thrombopoietin expands hematopoietic stem cells after transplantation.","volume":"110","author":"Fox","year":"2002","journal-title":"J Clin Invest"},{"issue":"13","key":"2019111817520914100_B39","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2014-01-547760","article-title":"Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.","volume":"123","author":"Bhagwat","year":"2014","journal-title":"Blood"},{"issue":"19","key":"2019111817520914100_B40","doi-asserted-by":"crossref","first-page":"13480","DOI":"10.1074\/jbc.274.19.13480","article-title":"Thrombopoietin signal transduction requires functional JAK2, not TYK2.","volume":"274","author":"Drachman","year":"1999","journal-title":"J Biol Chem"},{"issue":"50","key":"2019111817520914100_B41","doi-asserted-by":"crossref","first-page":"31680","DOI":"10.1016\/S0021-9258(18)31749-6","article-title":"Convergence of signaling by interleukin-3, granulocyte-macrophage colony-stimulating factor, and mast cell growth factor on JAK2 tyrosine kinase.","volume":"269","author":"Brizzi","year":"1994","journal-title":"J Biol Chem"},{"issue":"2","key":"2019111817520914100_B42","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0092-8674(93)90414-L","article-title":"JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.","volume":"74","author":"Witthuhn","year":"1993","journal-title":"Cell"},{"issue":"16","key":"2019111817520914100_B43","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1073\/pnas.1404354111","article-title":"Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation.","volume":"111","author":"Ng","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"2019111817520914100_B44","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2014-03-560441","article-title":"Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis.","volume":"124","author":"Meyer","year":"2014","journal-title":"Blood"},{"issue":"13","key":"2019111817520914100_B45","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2014-03-559815","article-title":"JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.","volume":"124","author":"Besancenot","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111817520914100_B46","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2011-09-380808","article-title":"Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.","volume":"120","author":"Yan","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2019111817520914100_B47","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1182\/blood-2011-08-372524","article-title":"Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.","volume":"119","author":"Pecquet","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111817520914100_B48","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111817520914100_B49","first-page":"184","article-title":"The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective.","volume":"1","author":"Staerk","year":"2012","journal-title":"JAKSTAT"},{"issue":"17","key":"2019111817520914100_B50","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111817520914100_B51","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1242\/dmm.006817","article-title":"Mouse models of myeloproliferative neoplasms: JAK of all grades.","volume":"4","author":"Li","year":"2011","journal-title":"Dis Model Mech"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/26\/3956\/1466143\/3956.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/26\/3956\/1466143\/3956.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T10:05:18Z","timestamp":1650449118000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/124\/26\/3956\/33681\/The-thrombopoietin-receptor-MPL-is-critical-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,18]]},"references-count":51,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2014,12,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-07-587238","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.723872554.793516211","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,18]]}}}